RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionThe information that I post is related, like ONCY's planned mBC registration study design being similar to Pfizer's Paloma and Daiichi's Destiny study designs, which lead to both drugs being approved through the FDA Accelerated Approval pathway.